March 6, 2020

Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In clinical practice alemtuzumab showed an acceptable safety profile in selected patients even if all of them suffered at least one adverse effect. Thorough and prolonged follow-up is required to further confirm the safety of this drug.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Castro et al. (Fri,) studied this question.

synapsesocial.com/papers/69df06bbd5404a0bea5916fb https://doi.org/https://doi.org/10.3233/jrs-191029

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Alemtuzumab CARE-MS I 5-year follow-up2017 · 224 citations
2Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis2018 · 590 citations
3Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis2008 · 1,011 citations
4Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria2017 · 8,033 citations
5Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy2012 · 1,233 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo